PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASES, CONTAINING CILOSTAZOL AS ACTIVE INGREDIENT
    3.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASES, CONTAINING CILOSTAZOL AS ACTIVE INGREDIENT 审中-公开
    用于治疗或预防含有作为活性成分的胆固醇的酒精性肝病的药物组合物

    公开(公告)号:US20130267558A1

    公开(公告)日:2013-10-10

    申请号:US13880792

    申请日:2011-10-07

    IPC分类号: A61K31/4709

    摘要: Provided is a pharmaceutical composition for the treatment and prevention of alcoholic liver diseases, including cilostazol as an active ingredient. Cilostazol inhibits expression levels of TNF-α and FAS (fatty acid synthase) gene in a concentration-dependent manner, and also significantly inhibits the activity of caspase-3. Accordingly, cilostazol shows superior effects for the treatment or prevention of alcoholic liver diseases, in particular, alcoholic hepatitis compared to pentoxifylline which is conventionally used as a therapeutic agent for the treatment for alcoholic hepatitis. Thus, cilostazol is suitable for use as a drug for the treatment or prevention of alcoholic hepatitis.

    摘要翻译: 提供了用于治疗和预防酒精性肝病的药物组合物,其包括西洛他唑作为活性成分。 西洛他唑以浓度依赖性方式抑制TNF-α和FAS(脂肪酸合成酶)基因的表达水平,并且还显着抑制半胱天冬酶-3的活性。 因此,与通常用作治疗酒精性肝炎的治疗剂的己酮可可碱相比,西洛他唑对酒精性肝病,特别是酒精性肝炎的治疗或预防具有优异的效果。 因此,西洛他唑适用于治疗或预防酒精性肝炎的药物。